Navigation Links
Kips Bay Medical Announces Closing of its $16.5 Million Initial Public Offering of Common Stock
Date:2/16/2011

MINNEAPOLIS, Feb. 16, 2011 /PRNewswire/ -- Kips Bay Medical, Inc. ("Kips Bay"), a development stage medical device company focused on developing, manufacturing and commercializing external saphenous vein support technology, or eSVS MESH, for use in coronary artery bypass grafting, or CABG, today announced that it has closed its previously announced offering of 2,062,500 shares of its common stock at a price of $8.00 per share.  

Kips Bay received aggregate net proceeds of approximately $13.6 million after deducting underwriting discounts and commissions and offering expenses payable by Kips Bay. Kips Bay expects to use the net proceeds of this offering to seek regulatory approval to market eSVS MESH in the United States and abroad, including human clinical trials in the United States; develop and test additional applications of eSVS MESH; make certain milestone payments for acquired intellectual property; and for working capital and general corporate purposes.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as sole book-running manager for the offering, and Newbridge Securities Corporation, Caris & Company and Chardan Capital Markets, LLC acted as co-managers.

A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting the U.S. Securities and Exchange Commission website at http://www.sec.gov. Alternatively, a copy of the prospectus related to this offering may be obtained from Rodman & Renshaw, LLC, Prospectus Department, 1251 Avenue of the Americas, New York, NY, 10020, telephone: 212-430-1710 or email: prospectus@rodm.com.

About Kips Bay Medical, Inc:  Kips Bay Medical, Inc., founded in 2007 and headquartered in Minneapolis, Minnesota, is a development stage medical device company focused on developing, manufacturing and commercializing its eSVS MESH for use in coronary artery bypass grafting surgery.  Additional information about Kips Bay Medical, Inc. can be found at www.kipsbaymedical.com.For further information, please contact:Kips Bay Medical, Inc.Manny Villafana, Chairman and Chief Executive OfficerScott Kellen, Chief Financial OfficerPhone: +1-763-235-3540Email: manny.villafana@kipsbaymedical.com
'/>"/>

SOURCE Kips Bay Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the ... has been granted Fast Track status by the US Food ... HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will ... sequential therapy targeting patients who are admitted to Emergency Departments ... ...
(Date:9/5/2017)... 2017  Just 18 months after its February 2016 ... announce the appointment of three new senior people to ... Dominic Jones-Phillips and James Wright bring ... Tammy Wynne joins as ... writers. She has over ten years, experience in global ...
(Date:8/31/2017)... YORK , Aug. 31, 2017 PM360,s ... industry,s must-read guide to the latest innovations happening across ... first industry publication to focus on providing a comprehensive ... Ultimately, the issue covers the most innovative companies, startups, ... "Everyone in this ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... medical device compliance and commercialization, has just released a new white paper ... is more adamant than ever about medical device, pharmaceutical, and combination product ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and industry-leading compliance software, The Guard®, has helped another long-time client pass their ... audit and properly satisfy the law. , Thanks to the help of the ...
(Date:9/20/2017)... ... , ... The Centers for Medicare and Medicaid Services (CMS) stated in the ... only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments over the ... on October 17, 2017 at 2 P.M. EST and uncover how you can ...
(Date:9/20/2017)... ... 2017 , ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: ... ADDICTION” is the creation of published author, Bill Miller. Bill Miller has ... including more than a decade of addiction to prescription drugs. He has ...
(Date:9/20/2017)... ... , ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl yearning to ... Jeanine Liston, a busy mother of five who used her time waiting for children to ... for over twenty years. It was a way to give some meaning to the ...
Breaking Medicine News(10 mins):